Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.

Rafael EstebanRaquel Domínguez-HernándezVictoria Martín-EscuderoMiguel Ángel Casado

Published in: PloS one (2022)

For Spain, SOF-based regimens offer value for HCV patients in terms of lowering HCV-related liver disease burden and generating significant cost savings for the health system, contributing to the WHO goal.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
human immunodeficiency virus
peritoneal dialysis
risk factors
patient reported
smoking cessation